Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03111901
Title Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer
Recruitment Withdrawn
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors William Grosh, MD
Indications

melanoma

renal cell carcinoma

Therapies

Aldesleukin + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.